The Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,200
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is:
- The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers.
Researchers will investigate the features, survival associated factors and other relevant factors of this population.
详细描述
The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is:
- The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers.
Researchers will investigate the features, survival associated factors and other relevant factors of this population.
The collected variables included: survival time, survival status, year of diagnosis, age, stage, molecular subtype statuses, histology, grade, and surgery, radiotherapy and systemic therapies utilization.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Biological sex is male;
- •Microscopically diagnosed as primary breast cancer.
排除标准
- •Presence of skin-origin malignancy on the breast.
结局指标
主要结局
Overall survival
时间窗: From the time of diagnosis to August 1, 2024 (anticipated).
The duration between the date of the first pathologic diagnosis and death from any cause or last follow-up.
次要结局
未报告次要终点
研究者
Ying Lin
MD, PhD
First Affiliated Hospital, Sun Yat-Sen University